BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY DANIEL FRANK CHRISTENSEN
The most lucrative unit of Novo Nordisk's business, Biopharm, has stopped capital from hemorrhaging and is in fact now restored to to growth.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Extra data boosts Lundbeck's agitation case
Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.
FDA confirms rejection of Y-mabs' cancer drug
The US Food and Drug Administration has officially rejected a Y-mabs cancer drug, after it was voted down by a sub-committee in October.
Top news from MedWatch this week
Miss anything?
Acquisitions to help Coloplast attain growth goal
Coloplast aims to grow by 10%, and chairman of the board Lars Rasmussen thinks this will be realized through multiple acquisitions.
FDA approves Ferring microbiotica-based treatment
Ferring Pharmaceuticals has received US approval for its stomach infection treatment.
Quality Assurance Specialist (QAS) in dietary supplements 
Principal Systems Engineer 
Head Of Business Unit Pharma, Öresund Region, AFRY 
Head of Regulatory Affairs Danmark 
External Manufacturing Leads 
(Senior) CMC Project Manager 
Associate Director, Global Drug Safety and Pharmacovigilance Scientist 
Laboratory assistants for an exciting QC department 
Chief consultant for Dansk Erhvervs Health and life science 
New Product Introduction Manager Nordics 
Strategic advisor and negotiator with in-depth knowledge of the pharmaceutical market 
Supply Chain Manager